Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable

Journal of Infectious Diseases

Volumn 183, Issue 7, 2001, Pages 1126-1129

  Drusano, G L ^a   Bilello, J A ^a,b   Preston, S L ^a   O'Mara E ^c   Kaul, S ^c   Schnittman, S ^d   Echols, R ^d  

^a ALBANY MEDICAL COLLEGE   (United States)

^b SRA Technologies Inc   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d Bristol Myers Squibb   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; VIRUS INHIBITION;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; OLIGOPEPTIDES; PYRIDINES; VIRAL LOAD; VIRUS REPLICATION;

EID: 0035313368     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/319281     Document Type: Article

References (8)

1. Effect of 2′,3′-dideoxy-3′-didehydrothymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies
2. Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro
3. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates
4. NPEM: A program for pharmacokinetic population analysis
5. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations
6. Human serum α-1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease
7. BMS-232632: Clinical trial AI424-007: Safety, efficacy of a once-daily protease inhibitor at 24 weeks